Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma

Yi Ye, Nicole N. Scheff, Daniel Bernabé, Elizabeth Salvo, Kentaro Ono, Cheng Liu, Ratna Veeramachaneni, Chi T. Viet, Dan T. Viet, John C. Dolan, Brian Schmidt

Research output: Contribution to journalArticle

Abstract

Oral cancer is often painful and lethal. Oral cancer progression and pain may result from shared pathways that involve unresolved inflammation and elevated levels of pro-inflammatory cytokines. Resolvin D-series (RvDs) are endogenous lipid mediators derived from omega-3 fatty acids that exhibit pro-resolution and anti-inflammatory actions. These mediators have recently emerged as a novel class of therapeutics for diseases that involve inflammation; the specific roles of RvDs in oral cancer and associated pain are not defined. The present study investigated the potential of RvDs (RvD1 and RvD2) to treat oral cancer and alleviate oral cancer pain. We found down-regulated mRNA levels of GPR18 and GPR32 (which code for receptors RvD1 and RvD2) in oral cancer cells. Both RvD1 and RvD2 inhibited oral cancer proliferation in vitro. Using two validated mouse oral squamous cell carcinoma xenograft models, we found that RvD2, the more potent anti-inflammatory lipid mediator, significantly reduced tumor size. The mechanism of this action might involve suppression of IL-6, C-X-C motif chemokine 10 (CXCL10), and reduction of tumor necrosis. RvD2 generated short-lasting analgesia in xenograft cancer models, which coincided with decreased neutrophil infiltration and myeloperoxidase activity. Using a cancer supernatant model, we demonstrated that RvD2 reduced cancer-derived cytokines/chemokines (TNF-α IL-6, CXCL10, and MCP-1), cancer mediator-induced CD11b+Ly6G myeloid cells, and nociception. We infer from our results that manipulation of the endogenous pro-resolution pathway might provide a novel approach to improve oral cancer and cancer pain treatment.

Original languageEnglish (US)
Pages (from-to)182-193
Number of pages12
JournalNeuropharmacology
Volume139
DOIs
StatePublished - Sep 1 2018

Fingerprint

Mouth Neoplasms
Analgesics
Squamous Cell Carcinoma
Neoplasms
Heterografts
Interleukin-6
Anti-Inflammatory Agents
Chemokine CXCL10
Cytokines
Inflammation
Lipids
resolvin D2
CXC Chemokines
Nociception
Neutrophil Infiltration
Omega-3 Fatty Acids
Myeloid Cells
Chemokines
Analgesia
Peroxidase

Keywords

  • Inflammation
  • Oral cancer
  • Pain
  • Resolvin
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. / Ye, Yi; Scheff, Nicole N.; Bernabé, Daniel; Salvo, Elizabeth; Ono, Kentaro; Liu, Cheng; Veeramachaneni, Ratna; Viet, Chi T.; Viet, Dan T.; Dolan, John C.; Schmidt, Brian.

In: Neuropharmacology, Vol. 139, 01.09.2018, p. 182-193.

Research output: Contribution to journalArticle

Ye, Y, Scheff, NN, Bernabé, D, Salvo, E, Ono, K, Liu, C, Veeramachaneni, R, Viet, CT, Viet, DT, Dolan, JC & Schmidt, B 2018, 'Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma', Neuropharmacology, vol. 139, pp. 182-193. https://doi.org/10.1016/j.neuropharm.2018.07.016
Ye, Yi ; Scheff, Nicole N. ; Bernabé, Daniel ; Salvo, Elizabeth ; Ono, Kentaro ; Liu, Cheng ; Veeramachaneni, Ratna ; Viet, Chi T. ; Viet, Dan T. ; Dolan, John C. ; Schmidt, Brian. / Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. In: Neuropharmacology. 2018 ; Vol. 139. pp. 182-193.
@article{2e6f8376ea79495d9d8e97590fee4784,
title = "Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma",
abstract = "Oral cancer is often painful and lethal. Oral cancer progression and pain may result from shared pathways that involve unresolved inflammation and elevated levels of pro-inflammatory cytokines. Resolvin D-series (RvDs) are endogenous lipid mediators derived from omega-3 fatty acids that exhibit pro-resolution and anti-inflammatory actions. These mediators have recently emerged as a novel class of therapeutics for diseases that involve inflammation; the specific roles of RvDs in oral cancer and associated pain are not defined. The present study investigated the potential of RvDs (RvD1 and RvD2) to treat oral cancer and alleviate oral cancer pain. We found down-regulated mRNA levels of GPR18 and GPR32 (which code for receptors RvD1 and RvD2) in oral cancer cells. Both RvD1 and RvD2 inhibited oral cancer proliferation in vitro. Using two validated mouse oral squamous cell carcinoma xenograft models, we found that RvD2, the more potent anti-inflammatory lipid mediator, significantly reduced tumor size. The mechanism of this action might involve suppression of IL-6, C-X-C motif chemokine 10 (CXCL10), and reduction of tumor necrosis. RvD2 generated short-lasting analgesia in xenograft cancer models, which coincided with decreased neutrophil infiltration and myeloperoxidase activity. Using a cancer supernatant model, we demonstrated that RvD2 reduced cancer-derived cytokines/chemokines (TNF-α IL-6, CXCL10, and MCP-1), cancer mediator-induced CD11b+Ly6G− myeloid cells, and nociception. We infer from our results that manipulation of the endogenous pro-resolution pathway might provide a novel approach to improve oral cancer and cancer pain treatment.",
keywords = "Inflammation, Oral cancer, Pain, Resolvin, Squamous cell carcinoma",
author = "Yi Ye and Scheff, {Nicole N.} and Daniel Bernab{\'e} and Elizabeth Salvo and Kentaro Ono and Cheng Liu and Ratna Veeramachaneni and Viet, {Chi T.} and Viet, {Dan T.} and Dolan, {John C.} and Brian Schmidt",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.neuropharm.2018.07.016",
language = "English (US)",
volume = "139",
pages = "182--193",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma

AU - Ye, Yi

AU - Scheff, Nicole N.

AU - Bernabé, Daniel

AU - Salvo, Elizabeth

AU - Ono, Kentaro

AU - Liu, Cheng

AU - Veeramachaneni, Ratna

AU - Viet, Chi T.

AU - Viet, Dan T.

AU - Dolan, John C.

AU - Schmidt, Brian

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Oral cancer is often painful and lethal. Oral cancer progression and pain may result from shared pathways that involve unresolved inflammation and elevated levels of pro-inflammatory cytokines. Resolvin D-series (RvDs) are endogenous lipid mediators derived from omega-3 fatty acids that exhibit pro-resolution and anti-inflammatory actions. These mediators have recently emerged as a novel class of therapeutics for diseases that involve inflammation; the specific roles of RvDs in oral cancer and associated pain are not defined. The present study investigated the potential of RvDs (RvD1 and RvD2) to treat oral cancer and alleviate oral cancer pain. We found down-regulated mRNA levels of GPR18 and GPR32 (which code for receptors RvD1 and RvD2) in oral cancer cells. Both RvD1 and RvD2 inhibited oral cancer proliferation in vitro. Using two validated mouse oral squamous cell carcinoma xenograft models, we found that RvD2, the more potent anti-inflammatory lipid mediator, significantly reduced tumor size. The mechanism of this action might involve suppression of IL-6, C-X-C motif chemokine 10 (CXCL10), and reduction of tumor necrosis. RvD2 generated short-lasting analgesia in xenograft cancer models, which coincided with decreased neutrophil infiltration and myeloperoxidase activity. Using a cancer supernatant model, we demonstrated that RvD2 reduced cancer-derived cytokines/chemokines (TNF-α IL-6, CXCL10, and MCP-1), cancer mediator-induced CD11b+Ly6G− myeloid cells, and nociception. We infer from our results that manipulation of the endogenous pro-resolution pathway might provide a novel approach to improve oral cancer and cancer pain treatment.

AB - Oral cancer is often painful and lethal. Oral cancer progression and pain may result from shared pathways that involve unresolved inflammation and elevated levels of pro-inflammatory cytokines. Resolvin D-series (RvDs) are endogenous lipid mediators derived from omega-3 fatty acids that exhibit pro-resolution and anti-inflammatory actions. These mediators have recently emerged as a novel class of therapeutics for diseases that involve inflammation; the specific roles of RvDs in oral cancer and associated pain are not defined. The present study investigated the potential of RvDs (RvD1 and RvD2) to treat oral cancer and alleviate oral cancer pain. We found down-regulated mRNA levels of GPR18 and GPR32 (which code for receptors RvD1 and RvD2) in oral cancer cells. Both RvD1 and RvD2 inhibited oral cancer proliferation in vitro. Using two validated mouse oral squamous cell carcinoma xenograft models, we found that RvD2, the more potent anti-inflammatory lipid mediator, significantly reduced tumor size. The mechanism of this action might involve suppression of IL-6, C-X-C motif chemokine 10 (CXCL10), and reduction of tumor necrosis. RvD2 generated short-lasting analgesia in xenograft cancer models, which coincided with decreased neutrophil infiltration and myeloperoxidase activity. Using a cancer supernatant model, we demonstrated that RvD2 reduced cancer-derived cytokines/chemokines (TNF-α IL-6, CXCL10, and MCP-1), cancer mediator-induced CD11b+Ly6G− myeloid cells, and nociception. We infer from our results that manipulation of the endogenous pro-resolution pathway might provide a novel approach to improve oral cancer and cancer pain treatment.

KW - Inflammation

KW - Oral cancer

KW - Pain

KW - Resolvin

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85053016156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053016156&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2018.07.016

DO - 10.1016/j.neuropharm.2018.07.016

M3 - Article

VL - 139

SP - 182

EP - 193

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -